Wellington Management Group LLP Buys 854,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Wellington Management Group LLP increased its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 352.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,096,744 shares of the company's stock after purchasing an additional 854,346 shares during the quarter. Wellington Management Group LLP owned approximately 1.42% of Replimune Group worth $13,282,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after purchasing an additional 1,083,633 shares during the period. Redmile Group LLC increased its position in shares of Replimune Group by 2.6% during the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock worth $59,406,000 after buying an additional 124,344 shares during the period. Vanguard Group Inc. increased its position in shares of Replimune Group by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock worth $43,546,000 after buying an additional 129,601 shares during the period. Tang Capital Management LLC raised its stake in Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after buying an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP lifted its holdings in Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after buying an additional 931,223 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Piper Sandler upped their target price on Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $19.75.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,952 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the sale, the insider now owns 146,933 shares in the company, valued at $1,184,279.98. This represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sushil Patel sold 25,105 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $202,346.30. Following the completion of the transaction, the chief executive officer now directly owns 343,576 shares in the company, valued at approximately $2,769,222.56. The trade was a 6.81% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is owned by company insiders.

Replimune Group Stock Up 0.6%

Shares of REPL stock traded up $0.06 on Wednesday, reaching $9.69. 1,033,156 shares of the company were exchanged, compared to its average volume of 946,846. Replimune Group, Inc. has a one year low of $4.93 and a one year high of $17.00. The company has a market cap of $746.97 million, a price-to-earnings ratio of -3.16 and a beta of 0.68. The company has a 50-day moving average of $8.35 and a 200-day moving average of $11.06. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.25) earnings per share. Analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.